Language selection

Search

Patent 2710090 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2710090
(54) English Title: ACETYLATION USING REDUCED VOLUME OF ACETIC ACID ANHYDRIDE FOR SYNTHESIZING NON-IONIC X-RAY CONTRAST AGENTS
(54) French Title: ACETYLATION AU MOYEN D'UN VOLUME REDUIT D'ACIDE ACETIQUE ANHYDRE POUR LA SYNTHESE D'AGENTS DE CONTRASTE NON IONIQUES POUR RAYONS X
Status: Deemed Abandoned and Beyond the Period of Reinstatement - Pending Response to Notice of Disregarded Communication
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07C 231/12 (2006.01)
  • A61K 49/00 (2006.01)
  • C07C 231/22 (2006.01)
  • C07C 237/46 (2006.01)
(72) Inventors :
  • CERVENKA, JAN (Norway)
  • HOLMAAS, LARS TERJE (Norway)
  • LARSEN, LEIF (Norway)
(73) Owners :
  • GE HEALTHCARE AS
(71) Applicants :
  • GE HEALTHCARE AS (Norway)
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued:
(22) Filed Date: 2010-07-20
(41) Open to Public Inspection: 2011-01-21
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
12/620,718 (United States of America) 2009-11-18
61/227,087 (United States of America) 2009-07-21

Abstracts

English Abstract


This invention relates to an improved method for the synthesis of 5-
acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide ("Compound
A"),
an intermediate in the industrial preparation of non-ionic X-ray contrast
agents. In
particular, it relates to acetylation of 5-amino-N, N'-bis(2,3-
dihydroxypropyl)-2,4,6-
triiodo-1,3-benzenedicarboxamide ("Compound B") using a reagent and solvent
mixture
containing between about 1.5 and about 3.0 liter of acetic anhydride and
acetic acid per
kilogram of Compound B. Preferably, following the acetylation reaction, the
reagent and
solvent mixture is distilled for re-use.


Claims

Note: Claims are shown in the official language in which they were submitted.


We claim:
1. A process for industrial preparation of 5-acetamido-N,N'-bis(2,3-
dihydroxypropyl)-
2,4,6-triiodoisophthalamide ("Compound A") using between about 1.5 and about
3.0 liter of
acetic anhydride and acetic acid as a reagent and solvent mixture per kilogram
of 5-amino-N,
N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide ("Compound
B") for
acetylation of Compound B.
2. The process according to claim 1, wherein said reagent and solvent mixture
is distilled,
following the acetylation reaction, for re-use.
3. A process for industrial preparation of 5-acetamido-N,N'-bis(2,3-
dihydroxypropyl)-
2,4,6-triiodoisophthalamide ("Compound A") by acetylating 5-amino-N, N'-
bis(2,3-
dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide ("Compound B") to
completion
using a blend of acetic anhydride and acetic acid with the latter as a
solvent.
4. The process according to claim 3, wherein said blend of acetic anhydride
and acetic acid is
distilled, following the acetylation reaction, for re-use.
7

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02710090 2010-07-20
PN0955
Acetylation using reduced volume of acetic acid anhydride for synthesizing non-
ionic X-
ray contrast agents
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims benefit of priority under 35 U.S.C. 119(e) to
United
States Provisional Application number 61/227,087 filed July 21, 2009, the
entire disclosure
of which is hereby incorporated by reference.
TECHNICAL FIELD
This invention relates generally to large-scale synthesis of non-ionic X-ray
contrast
agents. It further relates to an improved method for the synthesis of 5-
acetamido-N,N'-
bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide ("Compound A"), an
intermediate in
the industrial preparation of non-ionic X-ray contrast agents. In particular,
it relates to
acetylation of 5-amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-
benzenedicarboxamide ("Compound B") using a reduced amount of acetic anhydride
and
acetic acid as a reagent and solvent mixture.
BACKGROUND OF THE INVENTION
Non-ionic X-ray contrast agents constitute a very important class of
pharmaceutical
compounds produced in large quantities. 5-[N-(2,3-dihydroxypropyl)-acetamido]-
N,N'-
bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide ("iohexol"), 5-[N-(2-
hydroxy-3-
methoxypropyl)acetamido]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
isophthalamide
("iopentol") and 1,3-bis(acetamido)-N,N'-bis[3,5-bis(2,3-dihydroxypropyl-
aminocarbonyl)-
2,4,6-triiodophenyl]-2-hydroxypropane ("iodixanol") are important examples of
such
compounds. They generally contain one or two triiodinated benzene rings.
In particular, iodixanol, marketed under the trade name Visipaque , is one of
the
most used agents in diagnostic X-ray procedures. It is produced in large
quantities by GE
Healthcare in Lindesnes, Norway. The industrial production of iodixanol
involves a
multistep chemical synthesis as shown in Scheme I below. To reduce the cost of
the final
product, it is critical to optimize each synthetic step. Even a small
improvement in reaction
design can lead to significant savings in a large scale production.
The instant improvement is directed to the acetylation step, where 5-amino-
N,N'-
bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (Compound B) is
acetylated to produce
5-acetylamino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
(Compound A)
1

CA 02710090 2010-07-20
PN0955
using acetic anhydride as the acetylating reagent. See Scheme I below.
According to the
present invention, the reagent volume as well as the solvent volume used in
the acetylation
reaction are significantly reduced.
OH
HO O CH3O O 1-amino-2,3- HO ) N H
O
CH3OH propanediol
OH
HO &NO 2 CH3O O NO z HO,, N N02
O o
O}1 OH
H
H2 HO "ill N O IC HO,_,~N O
Acetic
OH OH H I I Anhydride
HO N NH 1-10 N I NI12
z
0 0 1
Compound B
OH
11
110N 0 OH H H Oil
Epichloro- HO 'A, N O O N OH
OH 1,/ hydrin I I I I
~ N OH Oil
1 10 N NH HOBiN H F]
\ N~N \ N,J,, OH
O I
O 0 1 OII I 0
Compound A
lodixanol
Scheme 1
SUMMARY OF THE INVENTION
The present invention provides an industrial process for preparing Compound A
by
acetylation of Compound B. Specifically, it uses between about 1.5 and about
3.0 liter of
acetic anhydride and acetic acid as a reagent and solvent mixture per kilogram
of Compound
B. In a preferred embodiment, following the acetylation reaction, the reagent
and solvent
mixture are distilled for re-use in a subsequent acetylation reaction from
Compound B to
Compound A.
2

CA 02710090 2010-07-20
PN0955
DETAILED DESCRIPTION OF THE INVENTION
In the acetylation reaction of Compound B, both the amino group and the
hydroxyl
groups are acetylated. While the hydroxyl groups are later deacetylated by the
addition of
aqueous sodium hydroxide, a full acetylation of Compound B involves the
addition of six
acetic anhydride equivalents (four 0-acetyls and two N-acetyls from four
hydroxyl groups
and two amino hydrogens respectively). See Scheme 2. Typically, acetic
anhydride is also
used as the solvent in the acetylation reaction to avoid introducing an
additional component
in the system. In such a design where no other solvent is present, the volume
of acetic
anhydride in the acetylation reaction typically exceeds more than 3.0 L per
kilogram of
Compound B.
HO OH HO OH
NH~ O O NHY
O 1 O/ O
I NH2 I NH
I= O
HO NH PI HO NH 1
HO HO J-j
Scheme 2
We have now surprisingly found that such high amount of acetic anhydride is
not
required to complete the acetylation reaction. The reaction can be led to
completion using a
blend of acetic anhydride and acetic acid with the latter as a solvent. In the
instant method,
the volume requirement for reagent and solvent in the acetylation reaction can
be
significantly reduced from the volume of acetic anhydride that has been
previously used.
Specifically, a combined volume of acetic anhydride and acetic acid between
about 1.5 and
about 3.0 liter per kilogram of Compound B can be safely and effectively
operated to
complete the acetylation reaction. In a preferred embodiment, the volume range
is about 1.5
and about 2.0 liter of acetic anhydride and acetic acid per kilogram of
Compound B.
Under the present procedure, the acetylation reaction solution is still
stirrable. The
exothermic nature in the acetylation reaction can be handled safely, and a
full conversion
from Compound B to Compound A may be obtained. The combination of acetic
anhydride
3

CA 02710090 2010-07-20
PN0955
and acetic acid further allows the excess reagent and solvent mixture to be
regenerated and
re-used in another batch of acetylation reaction.
The temperature of the reaction is typically in the range of about 50 to about
125 C,
gradually increasing as the exotherm in the reaction heats the reaction
mixture. In certain
embodiments, the acetylation reaction is preferably started at ambient
temperature. An acid
catalyst, such as sulphuric acid or p-toluene sulfonic acid, may also be added
in the
acetylation reaction.
The instant invention provides several distinct advantages. First, the amount
of
expensive acetic anhydride consumed per batch is reduced. In addition, because
acetic acid is
cheaper than acetic anhydride, the partial replacement of acetic anhydride
with acetic acid
lowers the reagent cost and in turn drives down the overall production cost
for the drug
product.
Second, the cost of manufacture is further lowered because energy costs and
process
time are reduced due to less volume of acetic anhydride and acetic acid to be
processed after
the acetylation reaction.
Finally, the instant method allows for a substantial amount of the excess
acetic
anhydride and acetic acid to be regenerated and re-used after the completion
of the
acetylation reaction. In a traditional approach where only acetic anhydride is
used without
acetic acid, reagent regeneration is impractical. Specifically, if pure acetic
anhydride is used
in the reaction, it is necessary to carry out each batch of acetylation with
100% acetic
anhydride. Thus, any regeneration of excess acetic anhydride requires a
complete separation
of acetic anhydride from acetic acid, the inevitable byproduct of the
acetylation reaction (one
mole of acetic anhydride gives one mole of acetylated product and one more of
acetic acid).
This separation involves a series of difficult and expensive processes.
The instant process, on the other hand, begins with the use of a mixture of
acetic
anhydride and acetic acid as a reagent and solvent mixture in the first batch
and continues to
use a mixture of acetic anhydride and acetic acid in subsequent batches. Thus,
excess acetic
anhydride and acetic acid are mixed with acetic acid byproduct from the
acetylation reaction
and the remixed acetic anhydride and acetic acid can be selected for
regeneration and re-use
for new batches of acetylation reaction. For example, after the acetylation
reaction, excess
acetic anhydride and acetic acid may be regenerated by distillation because
acetic acid has a
lower boiling point than acetic anhydride (1 l 8 C vs. 136 C at atmospheric
pressure). As
4

CA 02710090 2010-07-20
PN0955
shown in the examples below, a fraction of the distillate may be re-used in
the next batch of
acetylation reaction and mixed with fresh acetic anhydride to form the desired
total amount of
reagent and solvent mixture.
The invention is illustrated further by the following examples that are not to
be
construed as limiting the invention in scope to the specific procedures or
products described
in them.
EXAMPLES
EXAMPLE 1
Compound B (5356 kg) was suspended in a mixture of acetic anhydride and acetic
acid (10900 L, 2.0 L/kg Compound B, 91 v/v % acetic anhydride and 9 v/v %
acetic acid) at
ambient temperature. This mixture was prepared by mixing acetic anhydride
(8115 kg) and
regenerated acetic anhydride (3460 kg), the latter containing 66 v/v % acetic
anhydride and
34 v/v % acetic acid obtained from a previous batch. The mixture was heated to
55 C. Then,
p-toluene sulfonic acid (25 kg) was added and the reaction mixture was further
heated to
117 C over about 90 minutes. All solids were dissolved in the reaction, and
100 % of
Compound B was acetylated. The remaining acetic anhydride/acetic acid (8430 L)
was
distilled off under reduced pressure resulting in a highly viscous reaction
mixture. Forty-one
percent of the distillate could be re-used as reagent in a later batch without
a discrete
purification step.
EXAMPLE 2
Compound B (5356 kg) was suspended in a mixture of acetic anhydride and acetic
acid (7760 L, 1.45 L/kg Compound B, 87 v/v % acetic anhydride and 13 v/v %
acetic acid) at
ambient temperature. This mixture was prepared by mixing acetic anhydride
(6086 kg) and
regenerated acetic anhydride (2295 kg), the latter containing 48 v/v % acetic
anhydride and
52 v/v % acetic acid obtained from a previous batch. The mixture was heated to
55 C. Then,
p-toluene sulfonic acid (25 kg) was added and the reaction mixture was further
heated to
124 C over about 90 minutes. All solids were dissolved in the reaction, and
100 % of
Compound B was acetylated. The remaining acetic anhydride/acetic acid (5580 L)
was
distilled off under reduced pressure resulting in a very viscous reaction
mixture. Thirty-nine
5

CA 02710090 2010-07-20
PN0955
percent of the distillate could be re-used as reagent in a later batch without
a discrete
purification step.
All patents, journal articles, publications and other documents discussed
and/or cited
above are hereby incorporated by reference.
G

Representative Drawing

Sorry, the representative drawing for patent document number 2710090 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Application Not Reinstated by Deadline 2013-07-22
Time Limit for Reversal Expired 2013-07-22
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2012-07-20
Application Published (Open to Public Inspection) 2011-01-21
Inactive: Cover page published 2011-01-20
Inactive: IPC assigned 2010-10-19
Inactive: IPC assigned 2010-10-19
Inactive: IPC assigned 2010-10-19
Inactive: IPC assigned 2010-10-19
Inactive: First IPC assigned 2010-10-19
Reinstatement Requirements Deemed Compliant for All Abandonment Reasons 2010-08-31
Application Received - Regular National 2010-08-24
Filing Requirements Determined Compliant 2010-08-24
Letter Sent 2010-08-24
Inactive: Filing certificate - No RFE (English) 2010-08-24

Abandonment History

Abandonment Date Reason Reinstatement Date
2012-07-20

Fee History

Fee Type Anniversary Year Due Date Paid Date
Application fee - standard 2010-07-20
Registration of a document 2010-07-20
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
GE HEALTHCARE AS
Past Owners on Record
JAN CERVENKA
LARS TERJE HOLMAAS
LEIF LARSEN
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 2010-07-20 1 16
Description 2010-07-20 6 240
Claims 2010-07-20 1 24
Cover Page 2011-01-07 1 33
Courtesy - Certificate of registration (related document(s)) 2010-08-24 1 104
Filing Certificate (English) 2010-08-24 1 156
Reminder of maintenance fee due 2012-03-21 1 112
Courtesy - Abandonment Letter (Maintenance Fee) 2012-09-14 1 172
Correspondence 2010-08-25 1 22